Difference between revisions of "OpenSourceMalaria:GSK Amino-thienopyrimidine Series"

From OpenWetWare
Jump to: navigation, search
(Current Needs of This Project: added most of new to do list)
(Mechanism of Action)
 
(50 intermediate revisions by 4 users not shown)
Line 1: Line 1:
{{OSDDMalaria}}
+
{{OpenSourceMalaria}}
  
=OSDD Malaria Series 2: The Aminothienopyrimidine (ATP) Series=
+
=Open Source Malaria Series 3: The Aminothienopyrimidine (ATP) Series=
  
 
==Introduction==
 
==Introduction==
  
===Preamble===
+
===General Information===
  
This page describes a sub-project of the Open Source Drug Discovery for Malaria consortium. Background to how the project works can be found on the page that describes the first branch of the project: [[OSDDMalaria:Story so far]].
+
This page describes a project of the [http://opensourcemalaria.org Open Source Malaria Consortium]. This is the third series the consortium has investigated. For a description of the first series, and the approach taken by OSM, read [http://pubs.acs.org/doi/full/10.1021/acscentsci.6b00086 the first paper].
  
All experimental work in this branch of the project is described on an [http://malaria.ourexperiment.org/aminotpseries open lab book]; status updates for the project are posted on The Synaptic Leap website, for example [http://www.thesynapticleap.org/node/343 here]; and some discussions take place on the consortium's [https://plus.google.com/u/0/114702323662314783325/posts Google+] page and [http://twitter.com/osddmalaria Twitter] feed, which may be followed. All contributions are welcome, ideally in the public domain, though existing members may be contacted offline if absolutely necessary e.g. at [[User:Matthew Todd]].
+
In 2010, GlaxoSmithKline (GSK) released chemical and biological data pertaining to some 13,500 compounds that displayed potent antimalarial activity ''in vitro'' ([http://www.nature.com/nature/journal/v465/n7296/abs/nature09107.html Nature paper]). Medicinal chemists at the [http://www.mmv.org/ Medicines for Malaria Venture] (MMV) identified several compounds present in this dataset which they believed to be excellent starting points, possessing low molecular weight, good projected solubility, high potency, low cytotoxicity, no known intellectual property issues, clear ways to structural variation and, to the best of their knowledge, the compounds were not the subject of antimalarial research by any other group, and hence suitable for an open source project.  
  
===The Origin of this Antimalarial Drug Candidate and the Project's Approach===
+
Series 3 is the third such series to be investigated and based on an aminothienopyrimidine core.
  
In 2010, GlaxoSmithKline (GSK) released chemical and biological data pertaining to some 13,500 compounds that displayed potent antimalarial activity ''in vitro'' ([http://www.nature.com/nature/journal/v465/n7296/abs/nature09107.html Nature paper]). Medicinal chemists at the [http://www.mmv.org/ Medicines for Malaria Venture] (MMV) identified several compounds present in this dataset which they believed to be excellent hits. These two compounds had the combination of a drug-like profile (polar, low molecular weight, amenable to structural variation), high potency, low cytotoxicity, no known intellectual property issues, and to the best of their knowledge they were not the subject of antimalarial research by any other group, and hence suitable for an open source project.  
+
The high throughput nature of the GSK screen carries the possibility of a false positive, and thus the first step was to resynthesise the hit compound and confirm its antimalarial activity. This has been achieved, confirming the potency of the original hit. To see if the compound could be further optimised, the next step was be the synthesis of small sets of diverse analogs, as well as some exploration of the druggability (solubility, metabolic degradation etc) of the hit compound. If an interesting structure-activity relationship could be found, the compound might be suitable for lead optimisation. This is where the project is up to: to date all structural variation has resulted in a reduction in potency. The mechanism of action remains unknown.
  
This page details the development of ''one'' of these two compounds, based on an aminothienopyrimidine core. MMV has developed a set of [http://www.mmv.org/sites/default/files/uploads/docs/essential_info_for_scientists/Compound_progression_criteria.pdf compound progression criteria] and these should be used to inform the project.
+
==Key Documents/Datasets==
  
The high throughput nature of the GSK screen carries the possibility of a false positive, and thus the first step was to resynthesise the hit compound and confirm its antimalarial activity. To see if the compound could be further optimised, the next step would be the synthesis of small sets of diverse analogs, as well as some exploration of the druggability (solubility, metabolic degradation etc) of the hit compound. If an interesting structure-activity relationship could be found, the compound might be suitable for lead optimisation.
+
The To Do List: on Github, labelled with [https://github.com/OpenSourceMalaria/OSM_To_Do_List/labels/Series%203 Series 3].
  
==Current Needs of This Project==
+
[https://docs.google.com/document/d/1m9A3s8fJmEmz3Qjm1BdAHwc-prfHfMao9FGcQ5TPVwM/edit Google Doc of already-synthesised compounds in Series 3.]
  
This section describes the current To Do list for this project, and can be changed frequently. Data for the project will be accumulated in lower sections of this page. It is possible to comment/alter this page directly with an OpenWetWare account. Other venues for commenting/suggesting are [https://plus.google.com/u/0/b/114702323662314783325/114702323662314783325/posts G+], [http://www.thesynapticleap.org/malaria/community The Synaptic Leap], [https://twitter.com/OSDDMalaria Twitter] or the Lab Notebooks for the [http://malaria.ourexperiment.org/aminotpseries chemistry] or the [http://malaria.ourexperiment.org/biological_data biology].
+
Original Labtrove Lab Notebook for [http://malaria.ourexperiment.org/aminotpseries synthetic chemistry]
  
'''Guiding Principles''': <br>
+
Lab notebook for much of the [http://malaria.ourexperiment.org/biological_data biology].
1) Maintain low calculated logP values for suggested compounds (<5) <br>
 
2) Be mindful of molecular weight <br>
 
3) Aim for diversity, given OSM-S-106 arose from a phenotypic screen and has no known target/mechanism of action <br>
 
4) That there must be a reason for doing chemistry: Can analogs be obtained by other means, from other groups? Is the original hit the best compound? <br>
 
  
'''To Do''':
+
(Some older status updates for the project were posted on The Synaptic Leap website, for example [http://www.thesynapticleap.org/node/343 here]).
  
Latest round of biological evaluation here. Compound structures governed by what was accessible synthetically in the short term, in particular by what boronic acids could be made/bought.
+
The most recent experimental updates were [http://malaria.ourexperiment.org/aminotpseries/11470/Synthesis_of_34aminothieno32dpyrimidin6ylNNdimethylbenzenesulfonamide_TF181.html compounds made in Jan 2015] and [http://malaria.ourexperiment.org/biological_data/11127/Evaluation_of_some_remaining_series_3_compounds_and_series_4_pyridine_analogues.html evaluated in May 2015]. Planning sessions took place in [http://malaria.ourexperiment.org/the_osm_blog/7974/post.html Sept 2013].
  
Results: All changes had seriously deleterious effect on activity. Meta sulfonamide appears necessary for activity.  Morpholine is a poor replacement for amine. Results for XXXXX suggest that variation of amine is possible where there is some variation (i.e. removal) in the sulfonamide portion. Raises possibility that there might be two targets - one hit by the substituted pyrimidine and one by the aryl sulfonamide.
+
MMV has developed a set of [http://www.mmv.org/sites/default/files/uploads/docs/essential_info_for_scientists/Compound_progression_criteria.pdf compound progression criteria] and these should be used to inform the project.
  
Rationale for structures: Morpholine substitution was thought to have been sensible based on XXX. Longer side chain attached to amine in XXX was proposed because of XXX.
 
  
Solubility: In several cases there appeared to be some sort of solubility issues, though we had expected all these compounds to be highly soluble.
 
  
 +
==Guiding Objective for This Series==
  
Short term items:
+
1) Maintain low calculated logP values (ideally <3.5) for proposed compounds <br>
 +
2) Be mindful of molecular weight (try to keep <500) <br>
 +
3) Aim for structural diversity, given the original hit (OSM-S-106) arose from a phenotypic screen and has no known target/mechanism of action <br>
 +
4) There must be a reason for doing synthetic chemistry: Can analogs be obtained by other means, from other groups? Is the original hit actually the best compound? <br>
  
1. Morpholine group appears to be a bad substitution. Make other substitutions on the primary amine, such as one or two methyls. Route to that would likely be to take OSM-S-70, add dimethylamine, then brominate, then Suzuki. Action item for '''Althea'''.
 
2. How many more meta-substituted sulfonamides like OSM-S-106 exist in the literature? We've done this search before, but let's revisit. Action item for '''Alice'''.
 
3. We ordered several other meta-substituted boronic acids, some of which have now come in. We need to evaluate these. Action item on '''Althea'''.
 
4. Are there any doubly-substituted meta-boronic acids we could employ in the coupling? Action item on '''Alice'''.
 
5. TCMDC-132385 should be synthesised to check its activity, as well as the fragments without the fluoroaromatic, and with other aryls. Action item on '''Murray'''.
 
6. Ask GSK for any information they might have on known inactives around OSM-S-106 where there is variation in that pendant amine side chain. Action item on '''Mat'''.
 
7. Make OSM-S-106 with substitution of the amine with a methyl ether. Devise synthetic approach. Action item on '''Alice'''.
 
8. Approach Sue Charman's lab for solubility and metabolic assays on OSM-S-106. Action item on '''Mat'''.
 
  
Longer term items:
 
  
1. Synthesise des-amino OSM-S-106, i.e. substitute the amine for H on the pyrimidine. Who wants to do this?
 
2. Can OSM-S-106 be derivatised further, i.e. this compound as a starting point?
 
3. Can Murray's new bromo-regioisomer synthesis be used to make more diverse compounds. How risky is this in terms of the amount of methodology needed?
 
4. How easily can scaffold analogs of OSM-S-106 be accessed, such as furan, flipped thiophene isomers, pyrrole or indole structures, pyridine vs pyrimidine?
 
  
==Data on the Intial Hit==
+
See [http://malaria.ourexperiment.org/osdd_malaria_shared/7509/post.html May] and [http://malaria.ourexperiment.org/the_osm_blog/7974/Choosing_the_final_aminothineopyrimidine_compounds_for_synthesis_and_evaluation.html September] 2013 consultations for which ATP analogues should be targeted.
 +
 
 +
Latest round of biological evaluation [http://malaria.ourexperiment.org/uri/374 here]. Compound structures governed by what was accessible synthetically in the short term, in particular by what boronic acids could be made/bought.
 +
 
 +
'''Results''': All changes had seriously deleterious effect on activity. Meta sulfonamide appears necessary for activity.  Morpholine is a poor replacement for amine. Results for OSM-S-137 vs TCMDC 132385 (structures [http://malaria.ourexperiment.org/data/6233.html here] suggest that variation of amine is possible where there is some variation (i.e. removal) in the sulfonamide portion. Raises possibility that there might be two targets - one hit by the substituted pyrimidine and one by the aryl sulfonamide.
 +
 
 +
'''Rationale for structures''': Morpholine substitution was thought to have been sensible based on [http://malaria.ourexperiment.org/uri/283 this modelling analysis]. Longer side chain attached to amine in OSM-S-137 was proposed because of mild activity for TCMDC 132385 (again, comparison [http://malaria.ourexperiment.org/data/6233.html here]).
 +
 
 +
'''Solubility''': In several cases there appeared to be some sort of solubility issues, though we had expected all these compounds to be highly soluble.
 +
 
 +
 
 +
'''Short term TO DO items''':
 +
 
 +
1. Morpholine group appears to be a bad substitution. Make other substitutions on the primary amine, such as one or two methyls (dimethyl InChIKey CGTVWFYTOADSRO-UHFFFAOYSA-N). Route to that would likely be to take [http://malaria.ourexperiment.org/uri/30a OSM-S-70], add dimethylamine, then brominate, then Suzuki. Action item for '''Althea'''. <br>
 +
2. How many more meta-substituted sulfonamides like OSM-S-106 exist in the literature? We've done this search before (link?), but let's revisit. Action item for '''Alice'''. <br>
 +
''Answer: There are 59 commercially available meta-substituted boronic acid/esters from Boron Molecular as shown [https://plus.google.com/u/0/114702323662314783325/posts/3xrc1hKTQHd here].'' <br>
 +
3. We already ordered several other meta-substituted boronic acids, 10, 15 and 55 - ([https://plus.google.com/u/0/114702323662314783325/posts/3xrc1hKTQHd]), some of which have now come in (10 (OSM-S-135) and 15 (OSM-S-133) already synthesised and tested [http://malaria.ourexperiment.org/data/files/6202/testing_Mar13_data_page2.png]). We need to evaluate these. Action item on '''Althea'''. <br>
 +
4. Are there any doubly-substituted meta-boronic acids we could employ in the coupling? Action item on '''Alice'''. <br>
 +
''Answer: There are a few doubly-substituted meta-boronic acids/esters available from Sigma Aldrich as shown [https://plus.google.com/u/0/b/114702323662314783325/108348788732703883441/posts/159bmiMMJBg here].'' <br>
 +
5. [https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL586182 TCMDC-132385] should be synthesised to check its activity, as well as the fragments without the fluoroaromatic, and with other aryls. Action item on '''Murray'''. <br>
 +
6. Ask GSK for any information they might have on known inactives around OSM-S-106 where there is variation in that pendant amine side chain. Action item on '''Mat'''. <br>
 +
7. Make OSM-S-106 with substitution of the amine with a methyl ether (InChIKey RMRWXSBDYMDPPE-UHFFFAOYSA-N). Devise synthetic approach. Action item on '''Alice'''. <br>
 +
[[Image:Methyl ester route.png|thumb|center|540px|Proposed methyl ester route]] <br>
 +
8. Approach Sue Charman's lab for solubility and metabolic assays on OSM-S-106. Action item on '''Mat'''. <br>
 +
 
 +
'''Longer term items''':
 +
 
 +
1. Synthesise des-amino OSM-S-106 (NAPAWLMTRGMNSY-UHFFFAOYSA-N), i.e. substitute the amine for H on the pyrimidine. Who wants to do this? <br>
 +
2. Can OSM-S-106 be derivatised further, i.e. this compound as a starting point? <br>
 +
3. Can Murray's new [http://malaria.ourexperiment.org/uri/35a bromo-regioisomer synthesis] be used to make more diverse compounds. How risky is this in terms of the amount of methodology needed? <br>
 +
4. How easily can scaffold analogs of OSM-S-106 be accessed, e.g. furan (GSJDJXHDXORRDD-UHFFFAOYSA-N), flipped thiophene (NBFDNDWQCGJNHN-UHFFFAOYSA-N), pyrrole (XTMBLMGMAYOFBP-UHFFFAOYSA-N), indole (ZVHBDXVFFFLUQY-UHFFFAOYSA-N), pyridine vs pyrimidine (FCEYCXXGTFVWIS-UHFFFAOYSA-N)? <br>
 +
5. Order a selection of [https://plus.google.com/u/0/114702323662314783325/posts/3xrc1hKTQHd meta-substituted boronic acids/esters ] (based on [http://malaria.ourexperiment.org/osdd_malaria_shared/7509/post.html May 2013 consultation ]) to make some more thienopyrimidine analogues. <br>
 +
6. Synthesise some analogues containing sulfonamide bioisosteres such as sulfonimidamides. Inspired by this publication: DOI: 10.1002/cmdc.201200014. <br>
 +
 
 +
==The Intial Hit==
  
 
The original hit compound, [https://www.ebi.ac.uk/chemblntd/compound/results/9372/1/molweight/asc/mini TCMDC 135294], has the following structure:
 
The original hit compound, [https://www.ebi.ac.uk/chemblntd/compound/results/9372/1/molweight/asc/mini TCMDC 135294], has the following structure:
Line 99: Line 118:
  
 
'''Need''': Find owners of relevant compounds, and indicate whether they have been contacted.
 
'''Need''': Find owners of relevant compounds, and indicate whether they have been contacted.
 +
 +
Some possibles, identified from [http://115.146.93.123/quiz/quizzes/view/15 this poll]:
 +
*http://www.sciencedirect.com/science/article/pii/S0960894X09003552
 +
*http://onlinelibrary.wiley.com/doi/10.1002/qsar.200420038/abstract
 +
 +
The [http://pubs.acs.org/doi/abs/10.1021/jm401760c 2,4-diaminothienopyrimidines from Kelly Chibale's lab] have a very similar core to Series 3.
  
 
==Experimental Work==
 
==Experimental Work==
Line 104: Line 129:
 
===Biological Evaluation===
 
===Biological Evaluation===
  
Activity of initial hit: [http://malaria.ourexperiment.org/uri/27b February 2013]
+
Initial hit: [http://malaria.ourexperiment.org/uri/27b February 2013]
  
Activity of commercial analogs of initial hit: [http://malaria.ourexperiment.org/uri/1af Structures: October 2012], [http://malaria.ourexperiment.org/uri/1c3 Activity: November 2012]
+
Commercial analogs of initial hit: [http://malaria.ourexperiment.org/uri/1af Structures: October 2012], [http://malaria.ourexperiment.org/uri/1c3 Activity: November 2012]
  
Activity of synthesised analogs:  
+
Initial hit vs. [http://malaria.ourexperiment.org/biological_data/8329 late stage gametocyte assay] and [http://malaria.ourexperiment.org/biological_data/7840 liver stages].
 +
 
 +
Synthesised analogs:  
  
 
Small Fragments: [http://malaria.ourexperiment.org/uri/1a0 October 2012]
 
Small Fragments: [http://malaria.ourexperiment.org/uri/1a0 October 2012]
 +
 
First Major Analog Set: [http://malaria.ourexperiment.org/uri/374 April 2013]
 
First Major Analog Set: [http://malaria.ourexperiment.org/uri/374 April 2013]
 +
 +
GSK assessment in [http://malaria.ourexperiment.org/biological_data/10252/Single_Shot_Potencies_for_Compounds_Submitted_to_GSK.html June 2014], followed by OSM-S-142 vs initial hit: [http://malaria.ourexperiment.org/biological_data/10456/IC50_determination_of_Compounds_Sent_to_GSK.html July 2014]
 +
 +
Ion Regulation Assay (i.e. vs PfATP4): [http://malaria.ourexperiment.org/biological_data/10343/Ion_Regulation_Assay_for_OSM_Series_1_and_3.html July 2014]
 +
 +
Patrick Thomson's methyl analog PT-22-C1, [http://malaria.ourexperiment.org/biological_data/11339/Biological_activities_of_OSMS106_and_PT22C1.html December 2014].
 +
 +
Compounds from Edinburgh: [http://malaria.ourexperiment.org/biological_data/11127/Evaluation_of_some_remaining_series_3_compounds_and_series_4_pyridine_analogues.html Tom Foley and Jamie Scott, May 2015].
  
 
===Organic Synthesis===
 
===Organic Synthesis===
Line 121: Line 157:
 
It was envisioned that the hit compound could be generated using this convergent strategy. The thienopyrimidine scaffold was to be synthesised from the commercially available formamide and methyl 3-aminothiophene-2-carboxylate. The use of trivial heterocyclic chemistry was thought to be sufficient for the introduction of an amine at the 4-position of this scaffold, before the substitution at the 6-position by a halogen was to proceed using lithiation/halogenation. Meanwhile, the benzenesulfonamide moiety was to be generated by transforming the commercially available 3-bromobenzenesulfonamide into the relevant boronate ester. The thienopyrimidine scaffold (A) and benzenesulfonamide boronate ester (B) would then be united using a Suzuki coupling.
 
It was envisioned that the hit compound could be generated using this convergent strategy. The thienopyrimidine scaffold was to be synthesised from the commercially available formamide and methyl 3-aminothiophene-2-carboxylate. The use of trivial heterocyclic chemistry was thought to be sufficient for the introduction of an amine at the 4-position of this scaffold, before the substitution at the 6-position by a halogen was to proceed using lithiation/halogenation. Meanwhile, the benzenesulfonamide moiety was to be generated by transforming the commercially available 3-bromobenzenesulfonamide into the relevant boronate ester. The thienopyrimidine scaffold (A) and benzenesulfonamide boronate ester (B) would then be united using a Suzuki coupling.
  
The results of this synthetic effort are described hereinafter.
+
The synthesis of the "Twisted" analogs containing ortho-methyl groups, with the intention of improving solubility, is discussed in Github posts [https://github.com/OpenSourceMalaria/OSM_To_Do_List/issues/58 58], [https://github.com/OpenSourceMalaria/OSM_To_Do_List/issues/118 118] and [https://github.com/OpenSourceMalaria/OSM_To_Do_List/issues/161 161].
 +
 
 +
A pyridyl analog was proposed by Matt Tarnowski (GHI [https://github.com/OpenSourceMalaria/OSM_To_Do_List/issues/117 117]) but was not synthesised.
  
 
===Construction of the thienopyrimidine scaffold===
 
===Construction of the thienopyrimidine scaffold===
  
It was found that the desired ring closure of formamide and methyl 3-aminothiophene-2-carboxylate could not proceed in the conditions tested. This ring closure was instead carried out using formic acid and ammonium formate in lieu of formamide. Steps 2 and 3 proceeded without controversy to give the aminothienopyrimidine scaffold.
+
It was found that the desired ring closure of formamide and methyl 3-aminothiophene-2-carboxylate could not proceed in the conditions tested. This ring closure was instead carried out using formic acid and ammonium formate in lieu of formamide. Steps 2 and 3 (above) proceeded without controversy to give the aminothienopyrimidine scaffold.
 +
 
 +
Updated synthetic information of chlorinated scaffold:
 +
 
 +
Links to synthesis of central chlorinated scaffold:
 +
 
 +
[[Image:Chloro Synthesis.png|thumb|center|400px|Good Synthetic Approach for Key Chlorinated Intermediate]]
 +
 
 +
Starting material for this synthesis costs $226 per 25g (from?). The 4-chlorothienopyrimidine product is available from Acros for $293 per 25 g. *Given this, do we just buy it?* Or should we request some from an interested company as a contribution?
 +
 
 +
Links:
 +
http://malaria.ourexperiment.org/uri/2a4
 +
and
 +
http://malaria.ourexperiment.org/uri/2a6
 +
 
 +
InChI=1S/C6H3ClN2S/c7-6-5-4(1-2-10-5)8-3-9-6/h1-3H
  
 
===Completion of the halogenated aminothienopyrimidine scaffold===
 
===Completion of the halogenated aminothienopyrimidine scaffold===
Line 230: Line 283:
  
 
Woodward, R. B.; Eastman, R. H., Tetrahydrothiophene ("Thiophane") Derivatives. J. Am. Chem. Soc. 1946, 68 (11), 2229-2235.
 
Woodward, R. B.; Eastman, R. H., Tetrahydrothiophene ("Thiophane") Derivatives. J. Am. Chem. Soc. 1946, 68 (11), 2229-2235.
 +
 +
 +
 +
Text that needs incorporating above:
 +
 +
Old text that needs adapting then deleting
 +
Two other interesting-looking starting points from the GSK set, based on a [http://openwetware.org/wiki/OSDDMalaria:GSK_Triazolourea_Singleton triazolourea] and a [http://openwetware.org/wiki/OSDDMalaria:GSK_Amino-thienopyrimidine_Series thienopyrimidine], were the focus of [http://openwetware.org/wiki/User:Jim_Cronshaw James Cronshaw's] honours [http://figshare.com/articles/ThesisforUpload.pdf/102049 thesis] at Sydney University. The triazolourea (OSM-S-56) was found to be [https://plus.google.com/b/114702323662314783325/114702323662314783325/posts/QfynoBafbXt even more active] than the original GSK hit (TCMDS 134395). James has synthesised the [http://malaria.ourexperiment.org/aminotpseries/5827/Suzuki_coupling_using_the_same_conditions_that_are_used_to_generate_boronate_esters.html thienopyrimidine] series lead, and we are awaiting confirmation of the compounds antimalarial activity. If the lead compound is confirmed as active then it will be necessary to decide which, if either, of the series are to be taken on further. In general a strategy for the project is to decide as early as possible which series are looking attractive biologically, because there are still a lot of leads to pursue. If any of these structures look synthetically attractive to you based on your previous experience, please consider joining the project. Some of these molecules are quite straightforward to make and would be suitable for undergraduate lab classes.
 +
 +
/end of text that needs incorporating.
 +
 +
===Mechanism of Action===
 +
 +
Unknown.
 +
 +
[https://github.com/OpenSourceMalaria/OSM_To_Do_List/issues/503 Predictive modeling].
 +
[https://github.com/OpenSourceMalaria/OSM_To_Do_List/issues/501 SwissTarget Prediction report]
 +
 +
==How To Get Involved==
 +
 +
On the [http://opensourcemalaria.org/ landing page], click the "Join the Team" tab for info on ways to get involved. For those new to OSM, the best ways at the outset are [https://github.com/OpenSourceMalaria/OSM_To_Do_List/labels/Series%203 Github] and [https://twitter.com/O_S_M Twitter].

Latest revision as of 07:29, 19 June 2017

Malaria Scheme.png

Malaria Home        OSM So Far        Compound Series        Links        Open Source Research Home        Tech Ops        FAQ       


Open Source Malaria Series 3: The Aminothienopyrimidine (ATP) Series

Introduction

General Information

This page describes a project of the Open Source Malaria Consortium. This is the third series the consortium has investigated. For a description of the first series, and the approach taken by OSM, read the first paper.

In 2010, GlaxoSmithKline (GSK) released chemical and biological data pertaining to some 13,500 compounds that displayed potent antimalarial activity in vitro (Nature paper). Medicinal chemists at the Medicines for Malaria Venture (MMV) identified several compounds present in this dataset which they believed to be excellent starting points, possessing low molecular weight, good projected solubility, high potency, low cytotoxicity, no known intellectual property issues, clear ways to structural variation and, to the best of their knowledge, the compounds were not the subject of antimalarial research by any other group, and hence suitable for an open source project.

Series 3 is the third such series to be investigated and based on an aminothienopyrimidine core.

The high throughput nature of the GSK screen carries the possibility of a false positive, and thus the first step was to resynthesise the hit compound and confirm its antimalarial activity. This has been achieved, confirming the potency of the original hit. To see if the compound could be further optimised, the next step was be the synthesis of small sets of diverse analogs, as well as some exploration of the druggability (solubility, metabolic degradation etc) of the hit compound. If an interesting structure-activity relationship could be found, the compound might be suitable for lead optimisation. This is where the project is up to: to date all structural variation has resulted in a reduction in potency. The mechanism of action remains unknown.

Key Documents/Datasets

The To Do List: on Github, labelled with Series 3.

Google Doc of already-synthesised compounds in Series 3.

Original Labtrove Lab Notebook for synthetic chemistry

Lab notebook for much of the biology.

(Some older status updates for the project were posted on The Synaptic Leap website, for example here).

The most recent experimental updates were compounds made in Jan 2015 and evaluated in May 2015. Planning sessions took place in Sept 2013.

MMV has developed a set of compound progression criteria and these should be used to inform the project.


Guiding Objective for This Series

1) Maintain low calculated logP values (ideally <3.5) for proposed compounds
2) Be mindful of molecular weight (try to keep <500)
3) Aim for structural diversity, given the original hit (OSM-S-106) arose from a phenotypic screen and has no known target/mechanism of action
4) There must be a reason for doing synthetic chemistry: Can analogs be obtained by other means, from other groups? Is the original hit actually the best compound?



See May and September 2013 consultations for which ATP analogues should be targeted.

Latest round of biological evaluation here. Compound structures governed by what was accessible synthetically in the short term, in particular by what boronic acids could be made/bought.

Results: All changes had seriously deleterious effect on activity. Meta sulfonamide appears necessary for activity. Morpholine is a poor replacement for amine. Results for OSM-S-137 vs TCMDC 132385 (structures here suggest that variation of amine is possible where there is some variation (i.e. removal) in the sulfonamide portion. Raises possibility that there might be two targets - one hit by the substituted pyrimidine and one by the aryl sulfonamide.

Rationale for structures: Morpholine substitution was thought to have been sensible based on this modelling analysis. Longer side chain attached to amine in OSM-S-137 was proposed because of mild activity for TCMDC 132385 (again, comparison here).

Solubility: In several cases there appeared to be some sort of solubility issues, though we had expected all these compounds to be highly soluble.


Short term TO DO items:

1. Morpholine group appears to be a bad substitution. Make other substitutions on the primary amine, such as one or two methyls (dimethyl InChIKey CGTVWFYTOADSRO-UHFFFAOYSA-N). Route to that would likely be to take OSM-S-70, add dimethylamine, then brominate, then Suzuki. Action item for Althea.
2. How many more meta-substituted sulfonamides like OSM-S-106 exist in the literature? We've done this search before (link?), but let's revisit. Action item for Alice.
Answer: There are 59 commercially available meta-substituted boronic acid/esters from Boron Molecular as shown here.
3. We already ordered several other meta-substituted boronic acids, 10, 15 and 55 - ([1]), some of which have now come in (10 (OSM-S-135) and 15 (OSM-S-133) already synthesised and tested [2]). We need to evaluate these. Action item on Althea.
4. Are there any doubly-substituted meta-boronic acids we could employ in the coupling? Action item on Alice.
Answer: There are a few doubly-substituted meta-boronic acids/esters available from Sigma Aldrich as shown here.
5. TCMDC-132385 should be synthesised to check its activity, as well as the fragments without the fluoroaromatic, and with other aryls. Action item on Murray.
6. Ask GSK for any information they might have on known inactives around OSM-S-106 where there is variation in that pendant amine side chain. Action item on Mat.
7. Make OSM-S-106 with substitution of the amine with a methyl ether (InChIKey RMRWXSBDYMDPPE-UHFFFAOYSA-N). Devise synthetic approach. Action item on Alice.

Proposed methyl ester route

8. Approach Sue Charman's lab for solubility and metabolic assays on OSM-S-106. Action item on Mat.

Longer term items:

1. Synthesise des-amino OSM-S-106 (NAPAWLMTRGMNSY-UHFFFAOYSA-N), i.e. substitute the amine for H on the pyrimidine. Who wants to do this?
2. Can OSM-S-106 be derivatised further, i.e. this compound as a starting point?
3. Can Murray's new bromo-regioisomer synthesis be used to make more diverse compounds. How risky is this in terms of the amount of methodology needed?
4. How easily can scaffold analogs of OSM-S-106 be accessed, e.g. furan (GSJDJXHDXORRDD-UHFFFAOYSA-N), flipped thiophene (NBFDNDWQCGJNHN-UHFFFAOYSA-N), pyrrole (XTMBLMGMAYOFBP-UHFFFAOYSA-N), indole (ZVHBDXVFFFLUQY-UHFFFAOYSA-N), pyridine vs pyrimidine (FCEYCXXGTFVWIS-UHFFFAOYSA-N)?
5. Order a selection of meta-substituted boronic acids/esters (based on May 2013 consultation ) to make some more thienopyrimidine analogues.
6. Synthesise some analogues containing sulfonamide bioisosteres such as sulfonimidamides. Inspired by this publication: DOI: 10.1002/cmdc.201200014.

The Intial Hit

The original hit compound, TCMDC 135294, has the following structure:

GSK Thienopyrimidine Series: TCMDC 135294

This compound has attractive ALogP and molecular weight values. In the OSDD project it has the ID OSM-S-106. Its biological activity has been confirmed (see below).

Other instances of this compound:

ChEMBL 581088.

ChemSpider.

PubChem

Machine-readable data:

SMILES: Nc1ncnc2cc(sc12)c3cccc(c3)S(=O)(=O)N

InChI=1S/C12H10N4O2S2/c13-12-11-9(15-6-16-12)5-10(19-11)7-2-1-3-8(4-7)20(14,17)18/h1-6H,(H2,13,15,16)(H2,14,17,18)

Existing Analogs

If analogs of these compounds already exist, they should be explored.

In TCAMS Data Set

Need: Analysis and data associated with other relevant compounds in the GSK TCAMS data set.

Commercially-available

An analysis of which commercially-available compounds are available has been done, and several compounds purchased and evaluated.

Need: The availability of compounds changes quite often, and searches should be periodically carried out.

Other Sources (e.g. Academic Labs)

If promising-looking analogs are available from other sources, we can contact the owners and arrange local screening for activity. Post details here:

Need: Find owners of relevant compounds, and indicate whether they have been contacted.

Some possibles, identified from this poll:

The 2,4-diaminothienopyrimidines from Kelly Chibale's lab have a very similar core to Series 3.

Experimental Work

Biological Evaluation

Initial hit: February 2013

Commercial analogs of initial hit: Structures: October 2012, Activity: November 2012

Initial hit vs. late stage gametocyte assay and liver stages.

Synthesised analogs:

Small Fragments: October 2012

First Major Analog Set: April 2013

GSK assessment in June 2014, followed by OSM-S-142 vs initial hit: July 2014

Ion Regulation Assay (i.e. vs PfATP4): July 2014

Patrick Thomson's methyl analog PT-22-C1, December 2014.

Compounds from Edinburgh: Tom Foley and Jamie Scott, May 2015.

Organic Synthesis

A proposed synthesis for this hit compound was drawn up, and is shown below:

Proposed synthesis for the above compound

It was envisioned that the hit compound could be generated using this convergent strategy. The thienopyrimidine scaffold was to be synthesised from the commercially available formamide and methyl 3-aminothiophene-2-carboxylate. The use of trivial heterocyclic chemistry was thought to be sufficient for the introduction of an amine at the 4-position of this scaffold, before the substitution at the 6-position by a halogen was to proceed using lithiation/halogenation. Meanwhile, the benzenesulfonamide moiety was to be generated by transforming the commercially available 3-bromobenzenesulfonamide into the relevant boronate ester. The thienopyrimidine scaffold (A) and benzenesulfonamide boronate ester (B) would then be united using a Suzuki coupling.

The synthesis of the "Twisted" analogs containing ortho-methyl groups, with the intention of improving solubility, is discussed in Github posts 58, 118 and 161.

A pyridyl analog was proposed by Matt Tarnowski (GHI 117) but was not synthesised.

Construction of the thienopyrimidine scaffold

It was found that the desired ring closure of formamide and methyl 3-aminothiophene-2-carboxylate could not proceed in the conditions tested. This ring closure was instead carried out using formic acid and ammonium formate in lieu of formamide. Steps 2 and 3 (above) proceeded without controversy to give the aminothienopyrimidine scaffold.

Updated synthetic information of chlorinated scaffold:

Links to synthesis of central chlorinated scaffold:

Good Synthetic Approach for Key Chlorinated Intermediate

Starting material for this synthesis costs $226 per 25g (from?). The 4-chlorothienopyrimidine product is available from Acros for $293 per 25 g. *Given this, do we just buy it?* Or should we request some from an interested company as a contribution?

Links: http://malaria.ourexperiment.org/uri/2a4 and http://malaria.ourexperiment.org/uri/2a6

InChI=1S/C6H3ClN2S/c7-6-5-4(1-2-10-5)8-3-9-6/h1-3H

Completion of the halogenated aminothienopyrimidine scaffold

Substitution at the 6-position of this aminothienopyrimidine scaffold could not - in our experience - be carried out. Protection of the free amine at the 4-position was found to be a successful strategy for introducing the halogen at the 6-position, however, this method gave low yields. Using the chlorinated thienopyrimidone (X) in a lithiation/halogenation was found to be the most synthetically tractable way of introducing the desired functionality whilst maintaining workable yields (~50%). An amine was introduced at the 4-position using ammonium hydroxide solution in a sealed tube (120 °C).

Alternative Synthetic Strategies

The step that involves n-BuLi would best be avoided, and if a more direct route of arriving at the Suzuki coupling step could be discovered, that would take a potentially dangerous and difficult step out of the synthetic route.

One possibility, involving NIS and an ionic liquid such as 1-Butyl-3-methylimidazolium tetrafluoroborate (which our lab doesn't have, but which is available from Aldrich in catalytic quality from $247/5g), is found below:

[doi:10.1016/j.tetlet.2011.03.010 DOI]

[dx.doi.org/10.1139/V09-125 Here] is another alternative, where the direct iodonation of arenes can be carried out using oxone and NaI. Whether or not this would work in my compound, given selectivity issues, is something that I'll have to investigate.

This paper shows a method of direct halogenation of thiophenes. This uses [Bis(trifluoroacetoxy)iodo]benzene, which we don't have lying around, but which can be bought from Aldrich for $136/10g. The reactivity of thiophenes vs pyrimidines is something I'll have to look into. UPDATE: I've read Clayden et al. (2012, p 727) and I'm informed that pyridine is, generally speaking, terrible at electrophilic aromatic substitution reactions. My understanding is that pyrimidine has the same reactivity as does pyridine, so there shouldn't be any selectivity problems with any of these reactions (a result that was perhaps anticipated by the BuLi reaction proceeding at the alpha position on the thiophene ring in the first place).

--- July 9th.

The BuLi reactions have literature precedent. Heffron (2010) acheives a very similar reaction, albeit with protection of a pyrimidine position (which doesn't seem to be reacting in my case anyway). Snegaroff (2009) uses (TMP)3CdLi to acheive the metallation/iodination. This less harsh base can be used at rt. This author discovered the reagent, so they are probably interested in self promotion. In any case, there is precedent for the lithium metallation proceeding.

--- July 18th

A post on ChemForums suggested that the sulfur might react with the iodine. According to Joule & Mills (p. 234) this won't happen. "The five membered heterocycles do not react with electrophiles at the heteroatom." and "...in pyrrole, electrophilic addition at the nitroge would lead to a substantial loss of resonance stabilisation - the molecule would be converted into a cyclic butadiene, with an attached nitrogen carrying a positive charge localised on that nitrogen atom.

--- August 26

A search performed on SciFinder at 8:57pm revealed that the meta sulfonamide is NOT novel.

Generation of the Boronate Ester

Initially, the synthesis of a boronic acid was desired however, this could not be generated on these substrates. Instead, boronate esters were generated for the para- and meta-substituted boronate esters of interest.

Thiophene Starting Material Synthesis

Additionally, the thiophene available from Sigma Aldrich for $159/10g can be made from the following synthesis.

Proposed synthesis for the above compound

Analogs

TCMDC 135294 is part of a series with one other member, | TCMDC 135255, shown below:

TCMDC 135255

| ChEMBL639249 link.

| ChemSpider link.

SMILES: Nc1ncnc2cc(sc12)c3cccc(NC(=O)Nc4ccccc4)c3

InChI=1S/C19H15N5OS/c20-18-17-15(21-11-22-18)10-16(26-17)12-5-4-8-14(9-12)24-19(25)23-13-6-2-1-3-7-13/h1-11H,(H2,20,21,22)(H2,23,24,25)

A list of commercially available compounds with similar structures to the one I'm trying to synthesise were identified with much help from Iain Wallace. If you're reading this and are interested in donating samples of these compounds, please contact someone on the project.

Misc possible industry sources of compounds:

Iain Wallace created a cytoscape file which details purchaseable compounds related to the two series that I am trying to make. The file can be found here, and Cytoscape can be downloaded for free here (one will need to activate the chemviz plugin, which can be activated from within Cytoscape). The results of this work, in the form of a list of purchaseable compounds, can be found here

A list of the above compounds in .csv format, with InChi, InChiKey, SMILES and eMolecules identifiers, can be found here.

These compounds, and relevant data, are shown below:

OLD DATA NOW IRRELEVANT. REFER TO NEW DATA BELOW:

Two compounds have since become unavailable from Enamine. These are commercially available but with a less strict similarity search on emolecules. http://www.emolecules.com/cgi-bin/rene/visitor.cgi?h=c22c97319d83c434da71f7f53149d7d2aaf0fe3014125ab4

NewThienosFromEnamineR.png NewThienosFromEnamine1R.png

Synthesis of new analogues

This image presents some strategies for assessing SAR's on the aminothienopyrimidine core.

Variability.png

References

Honours Thesis by Jimmy Cronshaw (submitted and examined) entitled "Open Source Drug Discovery: Effort Toward the Synthesis and Evaluation of Two Antimalarial Drug Candidates" may be downloaded from Figshare. The thesis is in PDF form, but contains much of the early data on this page.

Barker, J. M.; Huddleston, P. R.; Wood, M. L., A RAPID CONVERSION OF 3-OXOTHIOLANES INTO 3-AMINOTHIOPHENES. Synthetic Communications 2002, 32 (16), 2565-2568.

Baykal, A. T.; Kakalis, L.; Jordan, F., Electronic and nuclear magnetic resonance spectroscopic features of the 1 ',4 '-iminopyrimidine tautomeric form of thiamin diphosphate, a novel intermediate on enzymes requiring this coenzyme. Biochemistry 2006, 45 (24), 7522-7528.

Brown, G. B.; Baker, B. R.; Bernstein, S.; Safir, S. R., BIOTIN. II. 3,4-trans-DIAMINOTHIOPHANE. The Journal of Organic Chemistry 1947, 12 (1), 155-159.

Castenado, G.; Dotson, J.; Goldsmith, R.; Gunzo, J.; Heffron, T.; Mathieu, S.; Oliveo, A.; Staben, S.; Sutherlin, D.P.; Tsui, V.; Wang, S.; Zhu, B.; Bayliss, T.; Chuckowree, I.; Folkes, A.; Wan, N.C. (Genentech, Inc., USA; Piramed Limited). Thienopyrimidine and furopyrimidine derivatives as phosphoinositide 3-kinase inhibitor and their preparation, pharmaceutical compositions and use in the treatment of cancer. World Intellectual Property Organisation 2008073785 A2, 2008; SciFinder Scholar AN 2008:735944 (accessed 2/2/2012).

Diel, B. N.; Han, M. C.; Kole, P. L.; Boaz, D. B., Synthesis of (C-13(6)-Ring-(U))-(+/-)-benzo(a)pyrene metabolites from (C-13(6)-Ring-(U))benzene. Journal of Labelled Compounds & Radiopharmaceuticals 2007, 50 (5-6), 551-553.

F, Duus., A study of the tautomerism of 2- and 4-ethoxycarbonylthiolan-3-ones implicating stereochemical effects of ring-substitution. Tetrahedron 1981, 37 (15), 2633-2640.

Son, J.B.; Jung, S. H.; Choi, W.I.; Jung, Y.H.; Choi, J.Y.; Song, J.Y.; Lee, K.H.; Lee, J.C.; Kim, E.Y.; Ahn, Y.G.; Kim, M.S.; Choi, HG.; Sim, T.B.; Ham, Y.J.; Park, D.; Kim, H.; Kim, D. (Hanmi Holdings Co., Ltd., S. Korea; Korea Institute of Science and Technology; Catholic University Industry Academic Cooperation Foundation). Preparation of thienopyrimidine derivatives for use as protein kinase inhibitors. World Intellectual Property Organisation 2011093684 A2, 2011; SciFinder Scholar AN 2011:971406 (accessed 3/2/2012).

Woodward, R. B.; Eastman, R. H., Tetrahydrothiophene ("Thiophane") Derivatives. J. Am. Chem. Soc. 1946, 68 (11), 2229-2235.


Text that needs incorporating above:

Old text that needs adapting then deleting Two other interesting-looking starting points from the GSK set, based on a triazolourea and a thienopyrimidine, were the focus of James Cronshaw's honours thesis at Sydney University. The triazolourea (OSM-S-56) was found to be even more active than the original GSK hit (TCMDS 134395). James has synthesised the thienopyrimidine series lead, and we are awaiting confirmation of the compounds antimalarial activity. If the lead compound is confirmed as active then it will be necessary to decide which, if either, of the series are to be taken on further. In general a strategy for the project is to decide as early as possible which series are looking attractive biologically, because there are still a lot of leads to pursue. If any of these structures look synthetically attractive to you based on your previous experience, please consider joining the project. Some of these molecules are quite straightforward to make and would be suitable for undergraduate lab classes.

/end of text that needs incorporating.

Mechanism of Action

Unknown.

Predictive modeling. SwissTarget Prediction report

How To Get Involved

On the landing page, click the "Join the Team" tab for info on ways to get involved. For those new to OSM, the best ways at the outset are Github and Twitter.